Cleavable linkers can break under specific biochemical conditions inside target cells, enabling rapid drug release
Curr Drug Deliv 2019;16:793-806.ArticlePubMed 31
There is really no feasible way to reduce the side effects of intravenous administration
With the shortage officially resolved, that allowance is being phased out
Glucagon-like peptide 1 receptor (GLP-1R), on the other hand, is primarily expressed in the pancreas, gut, central nervous system, and also found in other tissues like the heart, kidneys, and lungs
Unlike other treatments, works with the immune system to support a healthier inflammatory response, potentially helping with pain, energy, brain fog, and overall quality of life